ADIL

Adial Pharmaceuticals, Inc.

ADIL · CIK 1513525 · Annual (10-K) · Last 7 years

Financial Trends

Revenue
20182024
Net Income−$13M
20182024
Operating CF−$7M
20182024
Free Cash Flow
20182024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue———————
Cost of Revenue———————
Gross Profit———————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense———————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-2.72$-3.60$-0.51————
EPS (Diluted)$-2.72$-3.60$-0.51————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B———
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$-0.0B$-0.0B$-0.0B—$0.0B
Capital Expenditures——$0.0B$0.0B———
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies